Market Intelligence

Europe’s largest national in vitro diagnostics market is evolving post-COVID, under the effects of new digital laws, artificial intelligence-enabled devices, apps on prescription and the rising popularity of continuous glucose monitors. The VDGH industry association’s latest survey indicates a changing market landscape for IVDs in 2024.

Delays have plagued J&J's soft tissue surgical robot. However, the company has now solidified at least its near-term plan and hopes to commence trials later this year.

Views from medtech industry leaders and investors on the most significant uncertainties and opportunities facing the sector in 2024. 

At a webinar organized by the Association of the European Self-Care Industry, sustainability expert Onur Durmus, partner at ERM, gave an overview of the Corporate Sustainability Reporting Directive and what consumer health companies must do to ensure compliance.

Bayer's head of R&D and chief scientific officer David Evendon-Challis talked to Medtech Insight about the company's prescision health business, including a holistic and personalized approach to digital self-care.

Pear Therapeutics filed for Chapter 11 bankruptcy in April and sold its remaining assets in an auction for about $6m. The demise of one the pioneers in the prescription digital therapeutics industry highlights the challenges PDT developers face getting their products reimbursed.

“There’s no one company, government, person or technology who is positioned to ‘solve’ the health of the world,” notes Haleon's Nick Tate. Which is why OTC companies are partnering with tech firms large and small to create the next generation of consumer healthcare products and services. In the first part of an exclusive interview on the future of digital consumer health, Tate – who heads up the firm’s incubator business, Haleon NEXT – discusses some of the complications of tech innovation that make such collaboration attractive.

In an event hosted by the Medical Device Innovation Consortium, cybersecurity experts discussed a benchmark report on the state of cybersecurity in the device industry. The director of digital health product security policy at Medtronic previewed the updated Joint Security Plan.

CMR Surgical has grown rapidly since being founded just over eight years ago. However, unlike most other medtech companies, CMR is not selling a ~$30 diagnostic test, or a ~$5,000 pacemaker. It is selling a complex surgical robot, called Versius, with a price tag rumored to be in the seven figures. 

The UK’s diagnostics sector has faced “significant underinvestment” over recent years, according to researchers at health think tank The King’s Fund. A new report shows how the UK’s spending on diagnostics compares to other European countries.

There is to be a smooth transition at the top of the EU’s largest medtech industry association as news emerges that Oliver Bisazza will step into the CEO position from early January.

Diagnostics such as c-reactive protein tests are more sensitive than ever before, but manufacturers are still struggling to place them in primary care and community settings where they can make huge differences.

MedTech Europe’s latest annual report unveils facts and figures that contextualize the European market against the global stage and highlight which countries are leading the way for medtech sales and employment.

In this episode of Report Digest, UK-based reporter Barnaby Pickering speaks to analyst Carrie Neptune about three Meddevicetracker reports on drug delivery technology.

Kristen Pothier, global lead of KPMG’s health care and life sciences advisory service, spoke to Medtech Insight about the current deal making climate, and how it impacts the diagnostics sector.

After a runaway 2021 and a strong if bumpy first quarter of 2022, all health care product sectors underwent an investment dip in the second quarter, says Silicon Valley Bank. Healthtech in Europe remained a stand-out performer.